# VACCINE TREATMENT AND EVALUATION UNIT: PHASE I/II THERAPEUTIC TRIAL FOR CLOSTRIDIUM DIFFICILE

> **NIH NIH N01** · EMORY UNIVERSITY · 2021 · $41,506

## Abstract

This program is comprised of a consortium of individual contracts within academic centers and organizations that provide a ready resource for the design and conduct of clinical trials to evaluate promising products to combat infectious diseases. In general, products will be evaluated in normal healthy populations; however, access to special populations is also available.

## Key facts

- **NIH application ID:** 10371853
- **Project number:** 272201300018I-P00002-27200016-1
- **Recipient organization:** EMORY UNIVERSITY
- **Principal Investigator:** ROBERT MULLIGAN
- **Activity code:** N01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2021
- **Award amount:** $41,506
- **Award type:** —
- **Project period:** 2017-05-01 → 2021-12-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10371853

## Citation

> US National Institutes of Health, RePORTER application 10371853, VACCINE TREATMENT AND EVALUATION UNIT: PHASE I/II THERAPEUTIC TRIAL FOR CLOSTRIDIUM DIFFICILE (272201300018I-P00002-27200016-1). Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/grant/nih/10371853. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*